Longhorn Vaccines v. Spectrum Solutions — Appeal Voluntarily Dismissed After 733 Days
Longhorn Vaccines & Diagnostics challenged the patentability of Spectrum Solutions’ biological specimen collection and transport patents at the Federal Circuit. After 733 days of appellate proceedings, both parties jointly stipulated to dismiss the appeals — each bearing its own costs.
A Federal Circuit patentability appeal ends without a merits decision
Longhorn Vaccines & Diagnostics, LLC filed this appeal at the Court of Appeals for the Federal Circuit on 6 July 2023, challenging the patentability of two patents held by Spectrum Solutions, LLC: US8669240B2 and US9683256. Both patents relate to biological specimen collection and transport systems — a technology category with significant commercial relevance in diagnostics and public health supply chains.
The appeal was terminated on 8 July 2025 via a joint stipulation of voluntary dismissal. The Federal Circuit dismissed the appeals and ordered each party to bear its own costs. Critically, no merits ruling was issued: the court did not adjudicate the validity or invalidity of either patent, and the dismissal is silent on whether it carries prejudicial effect under the applicable procedural rules.
The 733-day duration before voluntary dismissal suggests the parties engaged in substantive negotiation or parallel proceedings before reaching resolution. The public record does not disclose whether a licensing arrangement, settlement payment, or commercial agreement underpins the joint stipulation. What remains unknown is whether Longhorn retains any right to re-challenge these patents in a future proceeding.
Filing to Voluntary dismissal in 733 days
733 days at the Federal Circuit — above the median for voluntarily resolved appeals
Voluntarily dismissed: what the joint stipulation means for both parties
Joint stipulation ends the appeal — no merits adjudication
A voluntary dismissal by joint stipulation means both parties agreed to terminate the Federal Circuit appeal without the court ruling on the underlying patentability questions. The Federal Circuit issued no finding on the validity of US8669240B2 or US9683256. The procedural effect — whether the dismissal operates with or without prejudice — is not specified in the public order, leaving that question open to interpretation.
No merits rulingThe public record is silent on prejudicial effect
Voluntary dismissals can be entered with or without prejudice, and the distinction matters enormously: a dismissal with prejudice bars re-litigation of the same claims, while one without prejudice preserves the right to re-challenge. The Federal Circuit’s order here does not specify which applies. Practitioners reviewing this case should not assume either outcome — the stipulation’s underlying terms, if any, are not publicly available.
Prejudice terms undisclosedSpectrum Solutions’ patents survive the appeal unchallenged on the merits
With no merits ruling, US8669240B2 and US9683256 remain intact and presumptively valid. Spectrum Solutions exits the Federal Circuit proceedings without any adverse finding against its specimen collection and transport patents. However, the absence of a merits affirmance means the patents have not received additional judicial validation — they remain subject to future challenge unless the dismissal terms privately bar re-litigation.
Patents remain validUncertainty persists for competitors in specimen collection technology
The unresolved patentability questions around biological specimen collection and transport systems leave competitors and product developers without judicial clarity. Companies operating in this space cannot rely on a merits ruling to inform design-around strategies or freedom-to-operate assessments. The joint cost order suggests a negotiated resolution, which may signal a commercial arrangement — but the scope of any such agreement remains undisclosed.
FTO clarity absentFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Longhorn Vaccines & Diagnostics, LLC | Company | Diagnostics IP licensor — holder of invalidity challenge against US8669240B2 and US9683256Search in Eureka ↗ |
| Defendant | Spectrum Solutions, LLC | Company | Spectrum Solutions, LLC — biological specimen collection and transport system patent holderSearch in Eureka ↗ |
| Plaintiff counsel | Nicole M. Jantzi | Attorney | Counsel for Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Fried, Frank, Harris, Shriver & Jacobson LLP | Law Firm | Representing Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Defendant counsel | Joseph F. Jennings | Attorney | Counsel for Spectrum Solutions, LLCSearch in Eureka ↗ |
| Defendant law firm | Knobbe Martens Olson & Bear, LLP | Law Firm | Representing Spectrum Solutions, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order is procedural rather than substantive: it records consent of both parties to end the appeals and imposes no cost sanction on either side. The equal cost-bearing provision is a standard feature of joint stipulations and does not reflect any judicial assessment of the merits. Critically, the order makes no finding on the patentability of US8669240B2 or US9683256 — the core issue on appeal — leaving the validity of both patents legally unchanged and presumptively intact.
US8669240B2 & US9683256 — Biological Specimen Collection and Transport
US8669240B2 (application no. US13/847202) and US9683256 (application no. US14/969339) both cover biological specimen collection and transport system technology. The later application number of US9683256 suggests it may be a continuation or related filing building on the earlier patent’s priority chain. These patents sit in a high-stakes diagnostic supply chain domain, covering the physical and chemical means by which biological samples are collected, preserved, and transported for laboratory analysis.
Specimen collection and transport technology has gained heightened commercial and regulatory visibility following the expansion of at-home and point-of-care diagnostics. Patents in this space can confer significant exclusivity over product form factors, preservation chemistries, and transport media — directly affecting device manufacturers, clinical laboratories, and public health procurement. The survival of these two patents through a Federal Circuit appeal without adverse finding strengthens Spectrum Solutions’ enforcement posture against competitors in this category.
Should you run an FTO against US8669240B2 and US9683256?
Any company developing, manufacturing, or commercialising biological specimen collection and transport systems should assess freedom-to-operate against US8669240B2 and US9683256. Both patents survived a Federal Circuit patentability appeal without a merits ruling, meaning they carry full presumption of validity. Product teams working on swab-based, liquid-based, or transport-media collection devices — including at-home test kits — are in the primary risk zone.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map claim scope across both patents, identify cited prior art from the prosecution history, and surface continuation or divisional filings that may extend the patent family’s reach. Given the unresolved estoppel questions around the dismissed appeal, an Eureka-assisted FTO analysis can also help identify whether any grounds raised in the underlying proceedings are now off-limits for future inter partes review.
Run a freedom-to-operate analysis on US8669240B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patentability appeals in diagnostics and specimen collection
Federal Circuit appeals involving patentability challenges to diagnostics and specimen collection patents — cases with comparable technology scope and voluntary or procedural resolution patterns.
What this case signals for the diagnostics and specimen collection IP landscape
A Federal Circuit appeal ending by joint stipulation in a patentability dispute typically signals commercial leverage shifting — or a parallel deal closing.
Voluntary Federal Circuit dismissals often mask commercial resolution
When both parties jointly stipulate to dismiss a Federal Circuit patentability appeal after over two years, the most common explanation is a negotiated commercial arrangement — licensing, acquisition, or market division. The equal cost-bearing order reinforces this: neither party was disadvantaged enough to demand cost recovery. IP teams tracking Spectrum Solutions or Longhorn should watch for licensing announcements or market activity.
Specimen collection patents remain a live enforcement risk without a merits ruling
US8669240B2 and US9683256 emerge from this appeal with their validity unchallenged in the court record. Any company developing or commercialising biological specimen collection and transport systems should treat these patents as fully enforceable. The dismissal does not reduce their enforceability — and the absence of a public settlement may mean Spectrum Solutions is positioned to enforce again.
Longhorn v Spectrum — key questions answered
The Federal Circuit appeal was voluntarily dismissed by joint stipulation on 8 July 2025. No merits ruling was issued on the patentability of US8669240B2 or US9683256. Each party was ordered to bear its own costs. The case had been pending for 733 days since filing on 6 July 2023.
Yes. Both patents retain their full presumption of validity. The voluntary dismissal produced no judicial finding on patentability. Neither patent was invalidated, cancelled, or found unenforceable. Competitors cannot rely on this dismissal as evidence of patent weakness.
The prejudicial effect depends on the terms of the stipulation, which are not publicly specified in the court order. If the underlying proceedings originated in an IPR, Longhorn Vaccines may face statutory estoppel under 35 U.S.C. § 315(e) limiting future challenges. Practitioners should conduct a full estoppel analysis before advising on re-challenge strategy.
The public record does not disclose the reason. Joint stipulations after extended appellate proceedings — here, over two years — are consistent with negotiated commercial resolution, including licensing agreements or market settlements. The equal cost-bearing order suggests neither party extracted a concession significant enough to shift costs.
Two patents were at issue: US8669240B2 (application no. US13/847202) and US9683256 (application no. US14/969339). Both cover biological specimen collection and transport system technology. The verdict cause was patentability, classified as an invalidity or cancellation action.
PatSnap Eureka searches patents and litigation data to answer instantly.